11 / 43
Incorporating immune-targeted therapies into the landscape
Ado-trastuzumab
emtansine (Kadcyla)
BREAST CANCER
Afatinib
(EGFR+)
LUNG CANCER
Gefitiinib
(EGFR+)
LUNG CANCER
Erlotinib
(EGFR+)
LUNG CANCER
Osimertinib (Tagrisso)
(T790M+)
LUNG CANCER
Crizotinib
(ALK/ROS/MET+)
LUNG CANCER
Alectinib
(ALK+)
LUNG CANCER
Dabrafenib+Trametinib
(BRAF V600E+)
LUNG CANCER
Vemurafenib (Zelboraf)
(BRAF+)
MELANOMA
Cetuximab (Erbitux)
(KRAS wt)
CCR
Dabrafenib (Tafinlar)
(BRAF V600+)
MELANOMA
Lapatinib (Tykerb)
(HER2+)
BREAST CANCER
Neratinib (Nerlynx)
(HER2+)
BREAST CANCER
Olaparib (Lynparza)
(BRCA-1+)
OVARIAN
Palbociclib (Ibrance)
(HR+/HER2-)
BREAST CANCER
Panitumumab (Vectibix)
(KRAS wt)
CCR
Pertuzumab (Perjeta)
(HER2+)
BREAST CANCER
Rucaparib (Rubraca)
(BRCA-1+)
OVARIAN
Trametinib (Mekinist)
(BRAF V600+)
MELANOMA
Trastuzumab (Herceptin)
(HER2+)
BREAST CANCER
Trastuzumab (Herceptin)
(HER2+)
GASTRIC CANCER
Cobimetinib (Cotellic)
(BRAF V600E/K+)
MELANOMA
Imatinib (Gleevec)
KIT+
GIST
Ribociclib (Kisqali)
(HR+/HER2-)
BREAST CANCER
Atezolizumab, PDL-1 (Tecentriq): Urothelial, Lung
Ipilimumab, CTLA-4 (Yervoy): Melanoma
Nivolumab, PD-1 (Opdivo): CRC (dMMR and MSI-H), Lung, H&N, Melanoma, Renal, Urothelial
Pembrolizumab, PD-1 (Keytruda): solid tumors (MSI-H), Lung PDL-1+, H&N, Melanoma